We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Schatz & Nobel has filed a lawsuit seeking class action against AtheroGenics
alleging the company violated federal securities laws by issuing false or misleading
public statements.
GenData has announced a collaborative sponsored research and exclusive license
agreement with Amgen for the discovery, development and commercialization of
therapeutics and diagnostics aimed at an undisclosed disorder.
Canadian biotech company AEterna Zentaris is entering the U.S. market with its
acquisition of Echelon Biosciences, a privately held company based in Salt Lake
City, Utah, for up to $5.6 million.
Genzyme has completed the transaction to buy back
the sales and marketing rights to Synvisc (hylan G-F 20) in the U.S. and five
European countries from Wyeth. The cash transaction is accretive to Genzyme.
The FDA's Division of Drug Marketing, Advertising and Communications (DDMAC)
has sent an untitled letter to Barr Pharmaceuticals informing the company it
has conducted false and misleading advertising for Seasonale tablets, a daily
birth control pill the company claims will help limit women's periods to just
four a year.
Pfizer was hit with another federal securities class action lawsuit for actions
related to its painkiller Celebrex, which last month was linked to a federal
study that showed the drug might cause adverse cardiovascular side effects.